Citations

Clear

1446 citation(s) found for "Howard, F".

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Chertkow, Howard , Jack, Clifford R. , Kawas, Claudia H. , Klunk, William E. , Mayeux, Richard , Mohs, Richard C. , Morris, John C. , Rossor, Martin N. , Scheltens, Philip , Carrillo, María C. , Thies, Bill, Weıntraub, Sandra , Phelps, Creighton H., McKhann, Guy M. , Knopman, David S. , Hyman, Bradley T. , Koroshetz, Walter J. , Manly, Jennifer J. , Jack, Clifford R , Scheltens, Philip , Morris, John C

Mayo Clinic

Alzheimer's & Dementia | April 22, 2011 | Volume: 7 | Issue: 3 | Pages: 263-269

10.1016/j.jalz.2011.03.005 | PMID 21514250 Get It

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available. We present criteria for all‐cause dementia and for AD dementia. We retained the general framework of probable AD dementia from the 1984 criteria. On the basis of the past 27 years of experience, we made several changes in the clinical criteria for the diagnosis. We also retained the term possible AD dementia, but redefined it in a manner more focused than before. Biomarker evidence was also integrated into the diagnostic formulations for probable and possible AD dementia for use in research settings. The core clinical criteria for AD dementia will continue to be the cornerstone of the diagnosis in clinical practice, but biomarker evidence is expected to enhance the pathophysiological specificity of the diagnosis of AD dementia. Much work lies ahead for validating the biomarker diagnosis of AD dementia.
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
Infante, Jeffrey R., Chiorean, E. Gabriela , Bendell, Johanna C. , Molina, Julian R. , Tibes, Raoul , Ramanathan, Ramesh K., Lewandowski, Karen, Lacouture, Mario E. , Langmuir, Virginia K., Lee, Hank, Kroll, Stew, Burris, Howard A. , Infante, Jon , Weiss, Glen J. , Borad, Mitesh J. , Jones, Suzanne Fields , Infante, Jon

Mayo Clinic

Clinical Cancer Research | March 18, 2011 | Volume: 17 | Issue: 9 | Pages: 2997-3004

10.1158/1078-0432.ccr-10-3425 | PMID 21415214 Get It

Abstract Purpose: The objectives of this phase 1, first-in-human study were to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), safety, pharmacokinetics, and preliminary activity of the hypoxia-activated prodrug TH-302 in patients with advanced solid tumors. Experimental Design: TH-302 was administered intravenously over 30 to 60 minutes in two regimens: three times weekly dosing followed by 1 week off (arm A) and every 3-week dosing (arm B). Results: Fifty-seven patients enrolled (arm A: N = 37 and arm B: N = 20). The TH-302 dose was escalated from 7.5 to 670 mg/m2 in arm A and from 670 to 940 mg/m2 in arm B. The most common adverse events were nausea, skin rash, fatigue, and vomiting. Hematologic toxicity was mild and limited. Grade 3 skin and mucosal toxicities were dose limiting at 670 mg/m2 in arm A; the MTD was 575 mg/m2. In arm B, grade 3 fatigue and grade 3 vaginitis/proctitis were dose limiting at 940 mg/m2; the MTD was 670 mg/m2. Plasma concentrations of TH-302 and the active metabolite Br-IPM (brominated version of isophosphoramide mustard) increased proportionally with dose. Two partial responses were noted in patients with metastatic small cell lung cancer (SCLC) and melanoma in arm A at 480 and 670 mg/m2. Stable disease was observed in arms A and B in 18 and 9 patients, respectively. Conclusions: The MTD of TH-302 was 575 mg/m2 weekly and 670 mg/m2 every 3 weeks. Skin and mucosal toxicities were DLTs. On the basis of responses in metastatic melanoma and SCLC, further investigations in these indications were initiated. Clin Cancer Res; 17(9); 2997–3004. ©2011 AACR.
An analysis of global research funding for the frontotemporal dementias: 1998–2008
Walentas, Christopher D., Shineman, Diana W., Horton, Antony , Fillit, Howard , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | January 27, 2011 | Volume: 7 | Issue: 2 | Pages: 142-150

10.1016/j.jalz.2010.11.010 | PMID 21276758 Get It

BackgroundTo better understand the status of frontotemporal dementia (FTD) research, and identify opportunities to accelerate translational research, we analyzed international funding for FTD and related dementias between 1998 and 2008.MethodsSearch terms were compiled to define the clinical spectrum of FTD and all known mechanisms. Funders were asked to return grants that contained these search terms in the title or abstract. Grants were classified according to the most reasonably achieved stated aim using a classification scheme of research activities that was developed to map grants along the continuum from basic research to clinical trials of treatments.ResultsThis analysis captured 613 grants ($432,167,275), from 19 private and public funders from 7 countries and the European Union. National Institutes of Health contributed $360 million (MM), 53% of grants and 83% of total funding. Foundations contributed $43 MM, 35% of grants and 10% of total funding, an increase in recent years. A total of $319 MM (74%, funding) went toward basic research, of which 10% was dedicated to preclinical treatment development, clinical treatment evaluation, and developing detection, diagnostic, and imaging technologies and reagents.ConclusionsFTD received moderate funding over the past decade, which has decreased almost five‐fold during this period. A sizable proportion of FTD funding supported mechanisms shared with Alzheimer's disease. Few programs advanced past validating target models and into drug discovery and preclinical development, indicating that the knowledge gained from recent research has still not advanced into treatment development. Quantitative analysis of funding highlighted under‐resourced areas as well as redundant efforts, enabling a more strategic approach toward advancing FTD drug discovery and development.
Randomized, Double-Blinded, Placebo-Controlled Crossover Trial of Treating Erectile Dysfunction with Sildenafil After Radiotherapy and Short-Term Androgen Deprivation Therapy: Results of RTOG 0215
Bruner, Deborah Watkins , James, J., Bryan, Charlene, Pisansky, Thomas M. , Rotman, Marvin, Corbett, Thomas, Speight, Joycelyn L., Byhardt, Roger W., Bentzen, Søren M. , Kachnic, Lisa A. , Berk, Lawrence , Sandler, Howard M. , Bruner, Deborah , Bentzen, Soren M

Mayo Clinic

The Journal of Sexual Medicine | January 14, 2011 | Volume: 8 | Issue: 4 | Pages: 1228-1238

10.1111/j.1743-6109.2010.02164.x | PMID 21235716 Get It

ABSTRACT Introduction Erectile dysfunction (ED) may be the most commonly observed adverse event (AE) associated with the combination of radiation therapy (RT) and androgen deprivation therapy (ADT). A significant number of men are trying phosphodiesterase type 5 inhibitors (PDE5s) such as sildenafil to treat ED, yet sildenafil studies to date shed little light on the response to ED after ADT. Aim The purpose of this trial was to evaluate sildenafil in the treatment of ED in prostate cancer patients previously treated with external beam RT and neoadjuvant and concurrent ADT. Methods In this randomized, double-blinded crossover trial, eligible patients received RT/ADT for intermediate risk prostate cancer and currently had ED as defined by the International Index of Erectile Function (IIEF). Patients were randomized to 12 weeks of sildenafil or placebo followed by 1 week of no treatment then 12 weeks of the alternative. Treatment differences were evaluated using a marginal model for binary crossover data. Main Outcome Measures The primary end point was improved erectile function, as measured by the IIEF. Results The study accrued 115 patients and 61 (55%) completed all three IIEF assessments. Sildenafil effect was significant (P = 0.009) with a difference in probabilities of erectile response of 0.17 (95% confidence interval: 0.06, 0.29), and 0.21 (0.06, 0.38) for patients receiving ≤120 days of ADT. However, as few as 21% of patients had a treatment-specific response, only improving during sildenafil but not during the placebo phase. Conclusions This is the first controlled trial to suggest a positive sildenafil response for ED treatment in patients previously treated with RT/ADT, however, only a minority of patients responded to treatment. ADT duration may be associated with response and requires further study. The overall low response rate suggests the need for study of additional or preventative strategies for ED after RT/ADT for prostate cancer.
O4‐08‐02: Prevention of Postmenopausal Alzheimer's Disease and Cognitive Loss with Replacement Estrogen (PREPARE) Study Results
Sano, Mary , Luo, Xiaodong , Andrews, Howard, Andrews, Karen L., Bell, Karen L. , Graff‐Radford, Neill R. , Lucas, John A. , Rabins, Peter V., Bolla, Karen I., Mitsis, Effie, Jacobs, Diane M.

Mayo Clinic

Alzheimer's & Dementia | October 26, 2010 | Volume: 6 | Issue: 4S_Part_20 | Pages: No page available

10.1016/j.jalz.2010.08.055 Get It

PGC-1 α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease
Liao, Zhixiang , Locascio, Joseph J. , Lesniak, Kristen A., Roderick, Sarah S., Watt, Marla L., Eklund, Aron C. , Zhang‐James, Yanli , Kim, Peter D., Hauser, Michael A. , Grünblatt, Edna , Moran, Linda, Mandel, Silvia, Riederer, Peter , Miller, Renee M. , Federoff, Howard J. , Papapetropoulos, Spyridon , Youdim, Moussa B. H. , Cantuti‐Castelvetri, Ippolita, Young, Anne B., Vance, Jeffery M. , Hedreen, John C. , Beach, Thomas G. , Graeber, Manuel B., Middleton, Frank A. , Rochet, Jean‐Christophe , Scherzer, Clemens R. , Papapetropoulos, Spyros , Zheng, Bin , Wüllner, Ullrich , Davis, Richard L. , Adler, Charles H.

Mayo Clinic

Science Translational Medicine | October 6, 2010 | Volume: 2 | Issue: 52 | Pages: No page available

10.1126/scitranslmed.3001059 | PMID 20926834 Get It

Abnormal expression of genes for energy regulation in Parkinson’s disease patients identifies a master regulator as a possible therapeutic target for early intervention.
Total Hip Arthroplasty with Shortening Subtrochanteric Osteotomy in Crowe Type-IV Developmental Dysplasia
Krych, Aaron J. , Howard, James L. , Trousdale, Robert T. , Cabanela, Miguel E., Berry, Daniel J. , Krych, Aaron J , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | September 15, 2010 | Volume: 92 | Issue: Supplement_1_Part_2 | Pages: 176-187

10.2106/jbjs.j.00061 | PMID 20844173 Get It

BACKGROUND: When surgeons perform total hip arthroplasty for hips with a high dislocation related to developmental dysplasia of the hip, obtaining long-term stable implant fixation and optimizing patient function remain challenges. The purpose of this paper was to evaluate the results of cementless arthroplasty with a simultaneous subtrochanteric shortening osteotomy in a group of patients with Crowe type-IV developmental dysplasia of the hip. METHODS: In a retrospective study, we evaluated the results and complications of twenty-eight consecutive primary cementless total hip arthroplasties in twenty-four patients (twenty women and four men), all of whom had Crowe type-IV developmental dysplasia of the hip. The arthroplasty was performed in combination with a subtrochanteric shortening osteotomy and with placement of the acetabular component at the level of the anatomic hip center. The patients were evaluated at a mean of 4.8 years postoperatively. RESULTS: The mean Harris hip score increased from 43 points preoperatively to 89 points at the time of final follow-up (p < 0.01). Twelve (43%) of the twenty-eight hips had an early or late complication or a reoperation. Two (7%) of the twenty-eight subtrochanteric osteotomies were followed by nonunion. There was one instance of isolated loosening of the femoral stem. One acetabular component loosened, and one acetabular liner disengaged. Four hips dislocated postoperatively. All remaining components were well-fixed at the time of the last radiographic follow-up. No sciatic neurapraxic injuries were identified. CONCLUSIONS: Cementless total hip arthroplasty combined with a subtrochanteric femoral shortening osteotomy in patients with a high hip dislocation secondary to developmental dysplasia was associated with high rates of successful fixation of the implants and healing of the osteotomy site and a mean postoperative Harris hip score of 89 points. The complication rate, however, was substantially higher than that associated with primary total hip arthroplasty in patients with degenerative arthritis. LEVEL OF EVIDENCE: Therapeutic Level IV . See Instructions to Authors for a complete description of levels of evidence. ORIGINAL ABSTRACT CITATION: “Total Hip Arthroplasty with Shortening Subtrochanteric Osteotomy in Crowe Type-IV Developmental Dysplasia” (2009;91:2213-21).
Definition of Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage as an Outcome Event in Clinical Trials and Observational Studies
Vergouwen, Mervyn D. I. , Vermeulen, Marinus, Gijn, J. van , Muizelaar, J. Paul, Mendelow, A. D. , Juvela, Seppo , Yonas, Howard, terBrugge, Karel G. , Macdonald, R. Loch , Diringer, Michael N. , Broderick, Joseph P., Dreier, Jens P. , Roos, Yvo B.W.E.M. , Rinkel, Gabriël J.E. , Wijdicks, Eelco F. M. , Broderick, Joseph

Mayo Clinic

Stroke | August 26, 2010 | Volume: 41 | Issue: 10 | Pages: 2391-2395

10.1161/strokeaha.110.589275 | PMID 20798370 Get It

Background and Purpose— In clinical trials and observational studies there is considerable inconsistency in the use of definitions to describe delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage. A major cause for this inconsistency is the combining of radiographic evidence of vasospasm with clinical features of cerebral ischemia, although multiple factors may contribute to DCI. The second issue is the variability and overlap of terms used to describe each phenomenon. This makes comparisons among studies difficult. Methods— An international ad hoc panel of experts involved in subarachnoid hemorrhage research developed and proposed a definition of DCI to be used as an outcome measure in clinical trials and observational studies. We used a consensus-building approach. Results— It is proposed that in observational studies and clinical trials aiming to investigate strategies to prevent DCI, the 2 main outcome measures should be: (1) cerebral infarction identified on CT or MRI or proven at autopsy, after exclusion of procedure-related infarctions; and (2) functional outcome. Secondary outcome measure should be clinical deterioration caused by DCI, after exclusion of other potential causes of clinical deterioration. Vasospasm on angiography or transcranial Doppler can also be used as an outcome measure to investigate proof of concept but should be interpreted in conjunction with DCI or functional outcome. Conclusion— The proposed measures reflect the most relevant morphological and clinical features of DCI without regard to pathogenesis to be used as an outcome measure in clinical trials and observational studies.
Cystic Fibrosis Gene Mutation in Two Sisters with Mild Disease and Normal Sweat Electrolyte Levels
Strong, Theresa V. , Smit, Lisa S., Turpin, Steven V., Cole, Jeffery L., Hon, Catherine Tom, Markiewicz, D., Petty, Thomas L., Craig, Michael W. Millar, Rosenow, Edward C., Tsui, Lap‐Chee, Iannuzzi, Michael C., Knowles, Michael R. , Collins, Francis S.

Mayo Clinic

New England Journal of Medicine | July 28, 2010 | Volume: 325 | Issue: 23 | Pages: 1630-1634

10.1056/nejm199112053252307 | PMID 1944451 Get It

HRCT of the Lung: Anatomic Basis, Imaging Features, Differential Diagnosis.
Jolles, Howard

Mayo Clinic

American Journal of Roentgenology | July 22, 2010 | Volume: 195 | Issue: 2 | Pages: W178-W178

10.2214/ajr.10.4331 Get It